Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/32807
Title: | Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial | Authors: | Takahashi, Kuniaki Wang, Rutao Kawashima, Hideyuki Tomaniak, Mariusz Gao, Chao Ono, Masafumi Hara, Hironori Wykrzykowska, Joanna J. de Winter, Robbert J. Werner, Nikos Teiger, Emmanuel Almeida, Manuel Barraud, Pascal Lantelme, Pierre Barlis, Peter Garg, Scot Hamm, Christian Steg, Philippe Gabriel Onuma, Yoshinobu VRANCKX, Pascal Windecker, Stephan Valgimigli, Marco Serruys, Patrick W. |
Issue Date: | 2020 | Publisher: | ELSEVIER IRELAND LTD | Source: | International journal of cardiology (print), 320 , p. 27 -34 | Abstract: | Backgrounds: Data on optimal antiplatelet therapy in patients undergoing stenting of the proximal left anterior descending artery (LAD) are limited. Methods: This is a post-hoc analysis of the GLOBAL LEADERS trial, a prospective, multi-center, randomized controlled trial, comparing the experimental strategy (1-month dual anti-platelet therapy [DAPT] followed by 23-month ticagrelor monotherapy) with the reference regimen (12-month DAPT followed by 12-month aspirin monotherapy) in relation to stenting of the proximal LAD. The primary endpoint was the composite of all-cause death or new Q-wave myocardial infarction (MI) and key secondary safety endpoint was Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at two years. Results: Among 15,845 patients included in the analysis, 3823 (23.9%) patients underwent stenting of the proximal LAD, while 12,022 (75.2%) did not. In the proximal LAD stenting group, there was no significant difference in the risk of the primary endpoint between the two antiplatelet strategies (3.38% vs. 3.93%; hazard ratio [HR]:0.86; 95% CI:0.62-1.20; P-interaction = 0.951). However, the risk of any MI (2.63% vs. 3.88%; HR:0.68; 95% CI:0.47-0.97; P-interaction = 0.015) and any revascularization (7.84% vs. 9.94%; HR:0.78; 95% CI:0.63-0.97; Pinteraction = 0.058) was significantly lower in the experimental strategy group, while demonstrating a similar risk of BARC type 3 or 5 bleeding between the two antiplatelet strategies (1.93% vs. 1.99%; HR:0.98; 95% CI:0.62-1.54; P-interaction = 0.981). Conclusions: The present study showed patients having stenting to the proximal LAD could potentially benefit from the experimental strategy with lower ischaemic events without a trade-off in major bleeding at two years. (C) 2020 Elsevier B.V. All rights reserved. | Notes: | Serruys, PW (corresponding author), Natl Univ Ireland, Intervent Med & Innovat, Galway NUIG, Galway, Ireland. patrick.w.j.c.serruys@gmail.com |
Other: | Serruys, PW (corresponding author), Natl Univ Ireland, Intervent Med & Innovat, Galway NUIG, Galway, Ireland. patrick.w.j.c.serruys@gmail.com | Keywords: | Dual antiplatelet therapy;Drug-eluting stent;Proximal left anterior artery descending artery;Ticagrelor monotherapy | Document URI: | http://hdl.handle.net/1942/32807 | ISSN: | 0167-5273 | e-ISSN: | 1874-1754 | DOI: | 10.1016/j.ijcard.2020.07.042 | ISI #: | WOS:000580594200008 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2021 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S0167527320335270-main.pdf Restricted Access | Published version | 1.47 MB | Adobe PDF | View/Open Request a copy |
WEB OF SCIENCETM
Citations
5
checked on Oct 6, 2024
Page view(s)
30
checked on Jul 20, 2022
Download(s)
4
checked on Jul 20, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.